Opus Genetics (IRD) Stock: Buy, Sell, or Hold?
IRD - Opus Genetics, Inc. Common Stock
$3.47
-0.35 (-9.16%)
▼
5d:
-9.64%
30d:
-28.75%
90d:
+3.58%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When IRD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IRD shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IRD shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IRD is currently trading at $3.47, which is considered oversold relative to its 30-day fair value range of $4.15 to $5.25.
Technical Outlook: Technically, IRD is in a uptrend. The price is currently testing key support at $3.44. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.2% recently.
Market Sentiment: IRD scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.47 (+288.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IRD is in a uptrend. The price is currently testing key support at $3.44. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.2% recently.
Market Sentiment: IRD scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.47 (+288.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.15 -
$5.25
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.2%)
- BULLISH: Trading 288.2% below Wall St target ($13.47)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.15 -
$5.25
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.44
Resistance Level
$4.88
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.85
Wall Street Target
$13.47
(+288.2%)
Revenue Growth (YoY)
-73.8%
Share & Embed Analysis
Last updated: October 24, 2026 1:56 PM ET
Data refreshes hourly during market hours. Next update: 2:56 PM
Data refreshes hourly during market hours. Next update: 2:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 64 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 35 SELL |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 61 BUY |